Medifast Q2 2026 revenue $76.4M (-27.6% YoY), net loss $3.1M; guides Q3 rev $60-80M

MEDIFAST INC

Revenue $76.4M, down 27.6% YoY; net loss $3.1M ($0.28 loss per share) vs net income $2.5M ($0.22 EPS) in Q2 2025.
Active earning coaches 11,700, down 48.7% YoY; revenue per active earning coach $6,529, up 41% YoY.
Gross profit margin 69.9% vs 72.6% YoY; SG&A as % of revenue 75.6% vs 73.6%.
Cash and investments $169.8M, no debt; working capital $160.5M.
Q3 2026 revenue guidance $60-80M, loss per share $0.15-0.65; full year 2026 revenue $270-300M, loss per share $0.25-1.75.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.